Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study-Reference-Cited by-同舟云学术

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study

Published:2016-02-02 Issue: Volume: Page:
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Adra Nabil,Albany Costantine,Brames Mary J.,Case-Eads Somer,Johnson Cynthia S.,Liu Ziyue,Fausel Christopher A.,Breen Timothy,Hanna Nasser H.,Hauke Ralph J.,Picus Joel,Einhorn Lawrence H.

Funder

Trial Supported by Merck & Co. Inc.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-016-3100-y.pdf

Reference23 articles.

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi: 10.3322/caac.21254

2. Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99(7):4592–4595. doi: 10.1073/pnas.072067999

3. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472–4478. doi: 10.1200/jco.2006.05.6382